1h Free Analyst Time
The leuprolide acetate market is forecasted to grow by USD 1.71 billion during 2024-2029, accelerating at a CAGR of 10.5% during the forecast period. The report on the leuprolide acetate market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of prostate cancer, rising availability of funds for research and development, and increasing healthcare expenditures and growing geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The leuprolide acetate market is segmented as below:
By End-user
- Hospitals
- Clinics
- Research and academic institiutions
By Route Of Administration
- Intramuscular
- Subcutaneous
- Intranasal
- Implantation
By Product Type
- Pre-filled syringes
- Vials
- Lyophilized powder
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the leuprolide acetate market covers the following areas:
- Leuprolide Acetate Market sizing
- Leuprolide Acetate Market forecast
- Leuprolide Acetate Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by End-user
9 Market Segmentation by Route of Administration
10 Market Segmentation by Product Type
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global leuprolide acetate market: AbbVie Inc., Aspen Oss B.V., Astellas Pharma Inc., Bachem AG, Beijing Biote Pharmaceutical Co. Ltd., Ferring BV, LG Chem Ltd., Livzon Pharmaceutical Group Inc., Merck KGaA, Midas Pharma GmbH, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Tolmar Pharmaceuticals Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is popularity of novel drug delivery systems."
According to the report, one of the major drivers for this market is the increasing prevalence of prostate cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aspen Oss B.V.
- Astellas Pharma Inc.
- Bachem AG
- Beijing Biote Pharmaceutical Co. Ltd.
- Ferring BV
- LG Chem Ltd.
- Livzon Pharmaceutical Group Inc.
- Merck KGaA
- Midas Pharma GmbH
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Tolmar Pharmaceuticals Inc.
